Burioni Roberto, Mancini Nicasio, De Marco Donata, Clementi Nicola, Perotti Mario, Nitti Giovanni, Sassi Monica, Canducci Filippo, Shvela Krisha, Bagnarelli Patrizia, Mascola John R, Clementi Massimo
Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Istituto Scientifico San Raffaele, Diagnostica e Ricerca San Raffaele, Milano, Italy.
PLoS One. 2008;3(10):e3423. doi: 10.1371/journal.pone.0003423. Epub 2008 Oct 16.
Antibodies against conserved epitopes on HIV-1 envelope glycoproteins (Env), such as the gp120 CD4-binding site (CD4bs), could contribute to protection against HIV-1. Env-based immunogens inducing such a response could be a major component of future anti-HIV-1 strategies. In this proof-of-concept study we describe the generation of two anti-idiotype (AI) murine antibodies mimicking the CD4bs epitope. Sera were collected from long-term non-progressor patients to obtain CD4bs-directed IgG, through sequential purification steps. The purified IgG were then used as Fab fragments to immunize mice for hybridoma generation. Two hybridomas (P1 and P2), reacting only against the CD4bs-directed IgG, were identified and characterized. The P1 and P2 antibodies were shown to recognize the idiotype of the broadly neutralizing anti-CD4bs human mAb b12. Both P1 and P2 Fabs were able to induce a strong anti-gp120 response in rabbits. Moreover, the rabbits' sera were shown to neutralize two sensitive tier 1 strains of HIV-1 in an Env-pseudotype neutralization assay. In particular, 3/5 rabbits in the P1 group and 1/5 in the P2 group showed greater than 80% neutralizing activity against the HXB2 pseudovirus. Two rabbits also neutralized the pseudovirus HIV-MN. Overall, these data describe the first anti-idiotypic vaccine approach performed to generate antibodies to the CD4bs of the HIV-1 gp120. Although future studies will be necessary to improve strength and breadth of the elicited neutralizing response, this proof-of-concept study documents that immunogens designed on the idiotype of broadly neutralizing Abs are feasible and could help in the design of future anti-HIV strategies.
针对HIV-1包膜糖蛋白(Env)保守表位(如gp120 CD4结合位点,CD4bs)的抗体可能有助于预防HIV-1。诱导这种反应的基于Env的免疫原可能是未来抗HIV-1策略的主要组成部分。在这项概念验证研究中,我们描述了两种模拟CD4bs表位的抗独特型(AI)鼠源抗体的产生。从长期非进展期患者中收集血清,通过连续纯化步骤获得针对CD4bs的IgG。然后将纯化的IgG用作Fab片段免疫小鼠以产生杂交瘤。鉴定并表征了两种仅与针对CD4bs的IgG反应的杂交瘤(P1和P2)。结果显示,P1和P2抗体可识别广泛中和性抗CD4bs人源单克隆抗体b12的独特型。P1和P2的Fab均能在兔体内诱导强烈的抗gp120反应。此外,在Env假病毒中和试验中,兔血清显示能中和两种敏感的HIV-1 1级毒株。特别是,P1组的5只兔中有3只,P2组的5只兔中有1只对HXB2假病毒表现出大于80%的中和活性。两只兔还中和了HIV-MN假病毒。总体而言,这些数据描述了首次通过抗独特型疫苗方法产生针对HIV-1 gp120 CD4bs的抗体。尽管未来还需要进行研究以提高所诱导中和反应的强度和广度,但这项概念验证研究证明,基于广泛中和抗体独特型设计的免疫原是可行的,有助于未来抗HIV策略的设计。